Recombinant Human ENA-78/CXCL5重组人CXCL5

Description :
FAQ COA 已发表文献 CXCL5, also known as epithelial cell-derived neutrophil-activating peptide (ENA-78), is an 8kDa proinflammatory member of the CXCchemokine family. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR-CXC chemokines which are angiostatic. CXCL5 is produced following stimulation of cells with the inflammatory cytokines interleukin-1 or tumor necrosis factor-alpha. It also can be detected in eosinophils, and can be inhibited with the type II interferon. Invivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis. Its up-regulation contributes to increased vascularization, tumor growth, and metastasis in many cancers. CXCL5 plays a role in reducing sensitivity to sunburn pain in some subjects, and is a potential target which can be utilized to understand more about pain in other inflammatory conditions like arthritis and cystitis. It elicits these effects by interacting with the cell surface chemokine receptor CXCR2. Product Properties Synonyms ENA-78 (5-78), CXCL5 (5-78), Neutrophil Activating Peptide ENA-78, Small-inducible cytokine B5 Accession P42830 GeneID 6374 Source E.coli-derived Human ENA-78,5-78 aa/CXCL5, Ala41-Asn114. Molecular Weight Approximately 8.1kDa. AA Sequence AAVLRELRCV CLQTTQGVHP KMISNLQVFA IGPQCSKVEV VASLKNGKEI CLDPEAPFLK KVIQKILDGG NKEN Tag None Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Purity > 97% by SDS-PAGE and HPLC analyses. Biological Activity The biological activity determined by a chemotaxis bioassay using human peripheral blood neutrophils is in a concentration of 10.0-100.0 ng/mL.Fully biologically active when compared to standard. Endotoxin EUper 1g of the protein by the LAL method. Formulation Lyophilized from a 0.2 m filtered concentrated solution in 20 mM PB, pH 7.4, 50 mM NaCl. Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20C. Further dilutions should be made in appropriate buffered solutions.